OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products.
The webinar titled “Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release” will be held on Monday 9 December 2024 at 16:00 GMT / 11:00 EST / 17:00 CET.
The webinar will feature presentations by:
- André Raposo, PhD, Director, Innovation Department at OXB
- Gareth McCathie, PhD, Group Lead, Innovation Department at OXB
- Thomas Evans, Principal Scientist, Innovation Department at OXB
The speakers will showcase OXB’s automation expertise in viral vector manufacturing, highlighting how automated systems and digital tools are used to optimise production processes and analytical workflows. The presentation will include case studies on transfection optimisation and the implementation of automated analytical methods such as qPCR, ELISA, and cell-based assays.
The presentations will be followed by a live Q&A session. To register for the webinar, please click here.
-Ends-
Enquiries:
OXB:
Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 509 737 / E: partnering@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life-changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.